National Research Corporation (NRCIA) Downgraded to Strong Sell at Zacks Investment Research
Zacks Investment Research cut shares of National Research Corporation (NASDAQ:NRCIA) from a hold rating to a strong sell rating in a research report report published on Friday morning.
According to Zacks, “National Research Corporation offers analytics and insights that facilitate revenue growth, patient, employee, customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. Its services include capture, interpretation, transmittal and benchmarking of critical data elements from various healthcare consumers. National Research Corporation is headquartered in Lincoln, Nebraska. “
Shares of National Research Corporation (NASDAQ:NRCIA) traded down $0.60 during midday trading on Friday, reaching $32.40. The company’s stock had a trading volume of 14,700 shares, compared to its average volume of 43,827. The company has a market cap of $678.55, a price-to-earnings ratio of 45.63 and a beta of 1.70. National Research Corporation has a fifty-two week low of $15.15 and a fifty-two week high of $41.99.
In other news, major shareholder K/I/E/Trust Under Agreement 3/ sold 2,127 shares of the stock in a transaction dated Wednesday, October 25th. The stock was sold at an average price of $38.00, for a total transaction of $80,826.00. Following the transaction, the insider now directly owns 5,655,489 shares in the company, valued at approximately $214,908,582. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 134,715 shares of company stock worth $4,996,670 over the last quarter. Corporate insiders own 37.54% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Royce & Associates LP grew its position in National Research Corporation by 92.5% during the 2nd quarter. Royce & Associates LP now owns 240,417 shares of the business services provider’s stock worth $6,467,000 after acquiring an additional 115,532 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC grew its position in National Research Corporation by 0.4% during the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,998,546 shares of the business services provider’s stock worth $53,761,000 after acquiring an additional 7,276 shares during the last quarter. Hillsdale Investment Management Inc. bought a new position in National Research Corporation during the 2nd quarter worth approximately $729,000. Goldman Sachs Group Inc. grew its position in National Research Corporation by 55.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 19,467 shares of the business services provider’s stock worth $524,000 after acquiring an additional 6,955 shares during the last quarter. Finally, Strs Ohio grew its position in National Research Corporation by 49.6% during the 3rd quarter. Strs Ohio now owns 18,100 shares of the business services provider’s stock worth $682,000 after acquiring an additional 6,000 shares during the last quarter. Institutional investors and hedge funds own 29.19% of the company’s stock.
National Research Corporation Company Profile
National Research Corporation, doing business as NRC Health, is a provider of analytics and insights for healthcare providers, payers and other healthcare organizations. The Company operates through six segments: Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Connect.
Receive News & Ratings for National Research Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.